In a deal potentially worth $3 billion, privately held Repare Therapeutics Inc., of Cambridge, Mass., and Montreal, entered a research collaboration with Bristol Myers Squibb Co. (BMS) to identify synthetic lethal precision oncology targets for drug candidates.
Positive preclinical data from Phio Pharmaceuticals Inc., of Marlborough, Mass., propelled the company stock (NASDAQ:PHIO) dramatically upward, about 86%, at midday Friday only to see it finally settle at a more modest 36.16% increase to close May 29 at $3.05.
Astrazeneca plc’s Tagrisso (osimertinib) seems poised to become standard of care in the adjuvant setting for early stage (IB, II and IIIA) EGFR-mutated non-small-cell lung cancer (NSCLC), thanks to phase III data from the study called Adaura, made public at the American Society of Clinical Oncology (ASCO) meeting.
DUBLIN – Johnson & Johnson’s Janssen Biotech arm is on the brink of a historic first vaccine approval, having secured a positive vote May 29 from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for its prime-boost Ebola virus vaccine combo, Zabdeno (Ad26.Zebov) plus MVABEA (MVA-BN-Filo).
HONG KONG – South Korea’s Qurient Co. Ltd., located in Gyeonggi-do, is preparing to send its novel drug, Q-702, into the clinic after receiving clearance from the U.S. FDA, roughly a month after submitting the application on April 24.
TORONTO – Vancouver, British Columbia-based Izotropic Corp. has inked a deal with Victoria, British Columbia-based based Starfish Medical Inc. to commercialize a CT scanner Izotropic CEO Robert Thast said will be a major disruptor of the breast imaging industry. Izotropic has spent approximately $20 million over the past 15 years to develop the system and is counting on Starfish to help translate this into a market-ready 3D breast CT imager by the end of 2020.
RSS
